Schering Corporation

Scott W Altmann

Xiaorui Yao

Michael P Graziano

Duane A Burnett

Harry R Davis

Maureen Laverty

Brian E Hawes

Robert A Kastelein

J Fernando Bazan

Nicholas J Murgolo

Fernando L Rock

Luquan Wang

Kim Anne O'Neill

Kim Ann O'Neill

Liji Zhu

The present invention provides, in part, methods for identifying inhibitors of NRIP1 and methods of using such inhibitors. Methods of treating NRIP1-mediated disorders using NRIP1 inhibitor are also provided.

NRIP1 regulation of apolipoprotein A1

The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.

NPC1L1 orthologues

The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Use of azetidinone compounds

We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels. Also, we claim a composition comprising said polypeptide bound to cholesterol or ezetimibe and a fusion protein comprising the polypeptide thereof.

NPC1L1 (NPC3) and methods of use thereof

Muteins, which are mutational variants of mammalian proteins. Particular positions of natural proteins are identified as critical in providing various different activities. Specific embodiments demonstrate properties of variations at these positions.

Mutational variants of mammalian proteins

Growing community of inventors

Fanwood, NJ, United States of America

Scott W Altmann